<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="other"><?DTDIdentifier.IdentifierValue http://null/schema/dtds/document/fulltext/xcr/xocs-article.xsd?><?DTDIdentifier.IdentifierType schema?><?SourceDTD.DTDName xocs-article.xsd?><?SourceDTD.Version 1.0?><?ConverterInfo.XSLTName ftrr2jats.xsl?><?ConverterInfo.Version 1?><?origin publisher?><?OLF?><front><journal-meta><journal-id journal-id-type="nlm-ta">Bull Acad Natl Med</journal-id><journal-id journal-id-type="iso-abbrev">Bull. Acad. Natl. Med</journal-id><journal-title-group><journal-title>Bulletin De L'Academie Nationale De Medecine</journal-title></journal-title-group><issn pub-type="ppub">0001-4079</issn><issn pub-type="epub">2271-4820</issn><publisher><publisher-name>Academie nationale de medecine</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7234785</article-id><article-id pub-id-type="publisher-id">S0001-4079(20)30256-9</article-id><article-id pub-id-type="doi">10.1016/j.banm.2020.05.042</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Anti-SARS-CoV-2 hyperimmune immunoglobulins, an urgent strategic choice</article-title></title-group><pub-date pub-type="pmc-release"><day>18</day><month>5</month><year>2020</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.--><pub-date pub-type="epub"><day>18</day><month>5</month><year>2020</year></pub-date><permissions><copyright-statement>&#x000a9; 2020 </copyright-statement><copyright-year>2020</copyright-year><license><license-p>Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.</license-p></license></permissions></article-meta></front></article>